|
|
|
|
Alkermes starts trial of new dependency-fighting drug
Alkermes reclaims Vivitrol commercialization rights from Cephalon [December 1, 2008] Genzyme looks for New Drug approval for leukemia treatment [November 24, 2008] FDA rejects efficacy of Targantas antibiotic [November 20, 2008]...
|
|
|
Alkermes Regains Full Commercialization Rights to VIVITROL in US
Alkermes, Inc.(NASDAQ: ALKS) today announced that it has regained from Cephalon, Inc. full commercialization rights to VIVITROL (naltrexone for extended-release injectable suspension) in the U.S. following a portfolio review by...
|
|
|
Alkermes regains rights to alcoholism drug Vivitrol
Cephalon has decided to return the US rights for the alcohol treatment Vivitrol to partner Alkermes, saying that the drug is not a core asset.Under the terms of the agreement, Cephalon will pay Alkermes $11 million to cover its...
|
|
|
Alkermes Regains Vivitrol Rights, Biogen Idec Heads for the Burbs, A Peek at Partners Innovation Funds Port
Several of the Boston areas public life sciences companies were making news this week.But first& Ryan delved into the , which was launched last year by Massachusetts General and Brigham and Womens hospitals to invest exclusively in...
|
|
|
Extended-Release Naltrexone, Treatment For Alcohol Dependence, Improves Quality-of-life Measures
Most studies examining the impact of alcohol-dependence (AD) treatment on quality-of-life (QOL) have looked at psychosocial treatments.This study looked at the impact of pharmacotherapy on QOL, specifically, the effects of extended...
|
|
|
Alkermes Regains Commercialization Rights to Vivitrol in U.S
GEN News Highlights GEN News Highlights Alkermesregained full commercialization rights to Vivitrol (naltrexone for extended-release injectable suspension) in the U.S.from Cephalon. The collaboration between the two companies will...
|
|
|
Alkermes reclaims Vivitrol commercialization rights from Cephalon
FDA warns of complications if Alkermes Vivitrol is injected incorrectly [August 12, 2008] Alkermes seeks FDA nod for bipolar disorder drug [July 24, 2008] Acusphere warned of Nasdaq delisting [July 16, 2008] Alkermes brings opioid...
|
|
|
Alkermes regains the rights to Vivitrol from Cephalon along with $120M in revenue
_ Alkermes regains the rights to Vivitrol from Cephalon along with $120M in revenue.
|
|
|
Alkermes (ALKS)' Deal with Cephalon, Inc. (CEPH) Ends; Raises '09 View
BANGALORE, Dec 1 (Reuters) - Biotechnology company Alkermes Inc said its collaboration with Cephalon Inc on Vivitrol, a treatment for alcohol dependence, was te Alkermes (ALKS)' Deal with Cephalon, Inc.(CEPH) Ends; Raises '09 View.<...
|
|
|
Alcohol-dependence study looks at impact of pharmacotherapy on quality-of-life
Most studies examining the impact of alcohol-dependence (AD) treatment on quality-of-life (QOL) have looked at psychosocial treatments.This study looked at the impact of pharmacotherapy on QOL, specifically, the effects of extended...
|
|
|
Cephalon and Alkermes Inc. end collaboration
Cephalon Inc.and Alkermes Inc. ended their collaboration on Vivitrol, a drug to treat alcoholism and being developed to fight drug dependence. Cephalon and Alkermes Inc. end collaboration.
|
|
|
Alkermes to take over anti-alcoholism drug
Vivitrol was developed by Alkermes (Nasdaq: ALKS) , a Cambridge biotech company, in partnership with Cephalon, Inc.(Nasdaq: CEPH). Alkermes to take over anti-alcoholism drug.
|
|
|
Alkermes Regains Full Commercialization Rights to VIVITROL in US
- Updates Financial Expectations to Reflect Independent Commercialization of VIVITROL - Cephalon will pay Alkermes $11 million to cover its share of the estimated losses on VIVITROL for the next 12 months and Alkermes will pay...
|
|
|
UPDATE 2-Alkermes' deal with Cephalon ends; raises '09 view
By Vidya L Nathan BANGALORE, Dec 1 (Reuters) - Biotechnology company Alkermes Inc said its collaboration with Cephalon Inc on Vivitrol, a treatment for alcohol dependence, was terminated, and raised its 2009 earnings view to reflect...
|
|
|
Alkermes Regains Full Commercialization Rights to VIVITROL in US
- Alkermes, Inc.(NASDAQ: ALKS) today announced that it has regained from Cephalon, Inc. full commercialization rights to VIVITROL (naltrexone for extended-release injectable suspension) in the U.S. following a portfolio review...
|
|
|
Alkermes Regains Full Commercialization Rights to VIVITROL in US
Alkermes, Inc.(NASDAQ: ALKS) today announced that it has regained from Cephalon, Inc. full commercialization rights to VIVITROL (naltrexone for extended-release injectable suspension) in the U.S. following a portfolio review by...
|
|
|
Alkermes Regains Full Commercialization Rights to VIVITROL in US
Alkermes, Inc.(NASDAQ: ALKS) today announced that it has regained from Cephalon, Inc. full commercialization rights to VIVITROL (naltrexone for extended-release injectable suspension) in the U.S. following a portfolio review by...
|
|
|
Alkermes Regains Full Commercialization Rights to VIVITROL(R) in US
--- Updates Financial Expectations to Reflect Independent Commercialization of VIVITROL - Alkermes, Inc.(NASDAQ: ALKS) today announced that it has regained from Cephalon, Inc. full commercialization rights to VIVITROL(R) ...
|
|
|
Cephalon ends Vivitrol venture with Alkermes
CAMBRIDGE, Mass.- Alkermes Inc. announced today that it has regained full commercialization rights in the United States for the alcoholism treatment Vivitrol. The biotechnology company said it has ended a collaboration with...
|
|
|
Alkermes Regains US Rights To Alcohol-Dependence Treatment
Alkermes Inc.(ALKS) sharply raised its fiscal-year outlook as the developer of drug-delivery systems regained the U.S.commercial rights to alcohol- dependence drug Vivitrol. The move allows Alkermes to record nearly $120 million...
|
|
|
Alkermes takes over Vivitrol commercialization
Alkermes Inc.announced Monday it has regained full commercialization rights in the United States for the alcoholism treatment Vivitrol. The biotechnology company said it has ended a collaboration with Cephalon Inc. (nasdaq: CEPH...
|
|
|
Cephalon, 2 others sue Mylan
CAMBRIDGE, Mass.- Alkermes Inc. announced today that it has regained full commercialization rights in the United States for the alcoholism treatment Vivitrol. The biotechnology company said it has ended a collaboration with...
|
|
|
Alkermes takes over Vivitrol commercialization
Alkermes takes over Vivitrol commercialization, ends agreement with Cephalon NEW YORK (Associated Press) - Alkermes Inc.announced Monday it has regained full commercialization rights in the United States for the alcoholism treatment...
|
|
|
Alkermes takes over Vivitrol commercialization
CAMBRIDGE, Mass.- Alkermes Inc. announced Monday it has regained full commercialization rights in the United States for the alcoholism treatment Vivitrol. The biotechnology company said it has ended a collaboration with Cephalon...
|
|
|
Alkermes takes over Vivitrol commercialization
CAMBRIDGE, Mass.(AP) -- Alkermes Inc. announced Monday it has regained full commercialization rights in the United States for the alcoholism treatment Vivitrol. The biotechnology company said it has ended a collaboration with...
|
